Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
We owe these early fighters a debt of gratitude for transforming our response to public health crises.
At the current pace, only about 20% of the world’s population will be vaccinated by the end of 2021.
Bamlanivimab and etesevimab may be given to people with mild to moderate COVID-19 who are at high risk for progression to severe disease.
Even as drugmakers ramp up supplies, only a trickle of the product has found its way into regular people.
Plitidepsin, derived from a sea squirt, may be far more potent than remdesivir against the coronavirus.
Full-dose anticoagulation treatment for moderately ill COVID-19 patients reduced the need for ventilators.
The ACTIV-2 study aims to determine whether neutralizing antibodies reduce the duration of COVID-19 symptoms.
Vaccines that stimulate immune responses against cancer using the mRNA technology may be fast-acting and cheap to make.
Two Phase III clinical trials are evaluating monoclonal antibodies for people hospitalized with moderate COVID-19.
In Los Angeles County, daily new COVID cases, deaths and hospitalizations have soared beyond their previous highs.
Lies infected America in 2020. The very worst were not just damaging, but deadly.
Agency grants emergency authorization for antibody cocktail given to President Trump.
Arthritis drug Olumiant (baricitinib) can be used in combination with remdesivir.
Effective, early interventions would benefit individual patients and healthcare system.
Recovery and death rates were similar in people treated with the anti-malaria drug or a placebo.
Bamlanivimab is now authorized for nonhospitalized people at high risk for progressing to severe COVID-19.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.